DrugPatentWatch Database Preview
Details for Patent: 7,816,396
Which drugs does patent 7,816,396 protect, and when does it expire?
Patent 7,816,396 protects CUVPOSA and is included in one NDA.
Summary for Patent: 7,816,396
| Title: | Method for increasing the bioavailability of glycopyrrolate |
| Abstract: | The invention relates to a method of treating sialorrhea in a human patient, which comprises orally administering glycopyrrolate in a liquid solution to the human patient under fasted conditions. |
| Inventor(s): | Roberts; Alan (Woodstock, GA), Venkataraman; Balaji (Alpharetta, GA) |
| Assignee: | Shionogi Pharma, Inc. (Atlanta, GA) |
| Application Number: | 12/648,068 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,816,396 |
|
Patent Claim Types: see list of patent claims | Use; Formulation; |
Drugs Protected by US Patent 7,816,396
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merz Pharms | CUVPOSA | glycopyrrolate | SOLUTION;ORAL | 022571-001 | Jul 28, 2010 | RX | Yes | Yes | Start Trial | Start Trial | REDUCE CHRONIC SEVERE DROOLING (I.E., SIALORRHEA)IN PATIENTS WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
